{"id":71143,"date":"2018-12-03T01:00:00","date_gmt":"2018-12-07T04:52:23","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/12\/07\/17b602beea\/"},"modified":"2018-12-07T12:52:27","modified_gmt":"2018-12-07T04:52:27","slug":"17b602beea","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/71143\/","title":{"rendered":"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx"},"content":{"rendered":"
\n
\n
\n
\n
\n

\"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx\"<\/p>\n

#Deals<\/span><\/strong>
<\/p>\n

\n
\n
\n
\n


<\/p>\n

\u4eca\u65e5<\/p>\n

Jassen\u65d7\u4e0b\u5b50\u516c\u53f8Cilag\u5ba3\u5e03<\/p>\n

\u4e0e\u6b27\u6d32\u836f\u4f01argenx\u8fbe\u6210\u5408\u4f5c\u534f\u8bae<\/p>\n

\u5171\u540c\u5f00\u53d1\u6297CD70\u5355\u514b\u9686\u6297\u4f53<\/p>\n

\u534f\u8bae\u9996\u4ed8\u6b3e\u4e3a3\u4ebf\u7f8e\u5143<\/p>\n

\u672a\u5305\u542b\u540e\u7eed\u91cc\u7a0b\u7891\u6b3e\u9879<\/p>\n

\u53e6\u5916<\/p>\n

JNJ\u8fd8\u5c06\u5411agenx SE\u8fdb\u884c\u80a1\u6743\u6295\u8d44<\/p>\n

\u503c\u5f97\u6ce8\u610f\u7684\u662f<\/p>\n

\u56fd\u5185\u5609\u548c\u751f\u7269\u66fe\u5f15\u8fdb\u8fc7\u8be5\u53f8\u4ea7\u54c1<\/p>\n

\u6297IL-6<\/span>\u5355\u6297<\/span>Gerilimzumab<\/p>\n

\u4e0d\u8fc7\u501f\u9053\u4e8e\u6b64\u524d\u83b7\u5f97\u72ec\u5bb6\u5f00\u53d1\u6743\u7684<\/p>\n

Anaphore->\u9510\u610f->Bird Rock Bio<\/p>\n

\u4f46\u4eca\u5e747\u6708\u4efd\u5df2\u7ecf\u53d8\u4e3aWithdraw<\/p>\n


<\/p>\n

\"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx\"<\/p>\n


<\/p>\n

Cusatuzumab(ARGX-110)<\/p>\n

First-in-Class\u7684\u6297CD70\u5355\u6297<\/p>\n

\u8be5\u5355\u6297\u53ef\u9776\u5411\u4e8eCD70<\/p>\n

\u4ece\u800c\u963b\u65ad\u5176\u4e0eCD27\u4ecb\u5bfc\u7684\u4fe1\u53f7\u901a\u8def<\/p>\n

\u6740\u6b7b\u80bf\u7624\u7ec6\u80de<\/p>\n

\u5e76\u6062\u590d\u514d\u75ab\u76d1\u89c6<\/p>\n

\u8be5\u4ea7\u54c1\u65e8\u5728\u4e34\u5e8a\u4e0a\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597
<\/p>\n

\u8840\u6db2\u7cfb\u7edf\u6076\u6027\u80bf\u7624\/\u5b9e\u4f53\u7624\/\u81ea\u8eab\u514d\u75ab\u75be\u75c5<\/p>\n

\u76ee\u524d\u4e34\u5e8a\u5728\u7814\u9002\u5e94\u75c7\u5305\u62ec<\/p>\n

\u76ae\u80a4T\u7ec6\u80de\u6dcb\u5df4\u7624CTCL<\/p>\n

\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5AML<\/p>\n

\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81MDS<\/p>\n

\u9f3b\u54bd\u764cNPC<\/p>\n

CTCL\u5355\u836f\u5904\u4e8e\u4e34\u5e8aII\u671f<\/p>\n

AML&MDS\u8054\u5408\u963f\u624e\u80de\u82f7\u5904\u4e8e\u4e34\u5e8aI\/II\u671f<\/p>\n

NPC\u5904\u4e8e\u4e34\u5e8aIb\u671f<\/p>\n


<\/p>\n

\"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx\"<\/p>\n

\"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx\"<\/p>\n


<\/p>\n

\u540c\u65f6\u4eca\u5929argenx\u516c\u5e03<\/p>\n

\u8054\u5408\u963f\u624e\u80de\u82f7I\/II\u671f\u7684\u4e00\u7ebfAML\u7ed3\u679c<\/p>\n

\u622a\u81f32018.10.15\u7684\u6570\u636e\u663e\u793a<\/p>\n

\u56db\u4e2a\u5242\u91cf\u7ec4\u4e34\u5e8a\u8010\u53d7\u6027\u826f\u597d<\/p>\n

ORR\u8fbe\u523092%(11\/12)<\/p>\n

\u5176\u4e2d<\/p>\n

CR\/CRi\u5360\u6bd491%(10\/11)<\/p>\n

PR\u5360\u6bd49%(1\/11)<\/p>\n

\u4e2d\u4f4d\u6301\u7eed\u7f13\u89e3\u65f6\u95f4\u4e3a8.1\u4e2a\u6708<\/p>\n

(2-17.4\u4e2a\u6708)<\/p>\n

5\u4e2a\u53d7\u8bd5\u8005\u5fae\u5c0f\u6b8b\u7559\u75c5\u68c0\u6d4b\u9634\u6027<\/p>\n


<\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n
\n


<\/p>\n


<\/section>\n

<\/section>\n
\n
<\/section>\n

\u201d<\/span><\/section>\n


<\/p>\n

We believe CD70 is an important target in the biology of select cancers, and we are eager to accelerate the development of this innovative antibody together with argenx. Phase 1\/2 data in acute myeloid leukemia showed the activity of cusatuzumab, and we hope to translate these findings to improve outcomes for patients with myeloid malignancies.<\/em>
<\/p>\n

\u2014\u2014 Yusri Elsayed, M.D., Ph.D.<\/strong><\/strong><\/span><\/p>\n

Vice President, Hematologic Malignancies Disease Area Leader, Janssen Research & Development<\/span><\/p>\n


<\/span><\/p>\n

<\/span><\/p>\n


<\/section>\n
\n
<\/section>\n

\u201d<\/span><\/section>\n


<\/p>\n


<\/p>\n

We are pleased to enter into this strategic partnership with argenx and advance a promising antibody for the treatment of AML and other blood cancers where current treatment is limited and effective new interventions are needed for patients. The addition of cusatuzumab deepens our portfolio and adds to our expertise in oncology, and more importantly, it reflects our commitment to combine Janssen’s strengths with those of other outstanding teams to advance science that we believe can transform the treatment of diseases and the lives of patients worldwide.<\/em>
<\/p>\n

\u2014\u2014Mathai Mammen, M.D., Ph.D.<\/strong><\/span><\/p>\n

Global Head, Janssen Research & Development<\/span><\/p>\n


<\/span><\/p>\n

\"Janssen\u5b50\u516c\u53f8Cilag\u534f\u8bae\u83b7\u5f97\u6297CD70\u5355\u6297Cusatuzumab\u5168\u7403\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6765\u81eaargenx\"<\/p>\n

Recent Approvals\/Potential Filings<\/span><\/p>\n


<\/p>\n

\n


<\/p>\n

<\/span><\/strong><\/p>\n

\u4ee5\u4e0b\u70ba\u5ee3\u544a\u5167\u5bb9<\/span><\/strong><\/span><\/p>\n

\n

\u9451\u65bc\u6b64\u524d\u516c\u76ca\u6350\u52a9\u91d1\u984d\u8f03\u5c11\uff0c\u540c\u6642\u8003\u616e\u5718\u968a\u904b\u71df\u6210\u672c\uff0c\u6211\u5011\u5f15\u5165\u4e86\u5fae\u4fe1\u5718\u968a\u7684\u6d41\u91cf\u4e3b\u529f\u80fd\uff0c\u6309\u7167\u5176\u5206\u6210\u898f\u5247\uff0c\u6211\u5011\u53ef\u4ee5\u7372\u5f97\u5176\u5ee3\u544a\u6536\u5165\u7684\u4e94\u6210\u5de6\u53f3\uff0c\u96d6\u7136\u9019\u4e5f\u662f\u4e00\u500b\u6bd4\u8f03\u4f4e\u7684\u6578\u5b57\uff0c\u4f46\u537b\u9ad8\u65bc\u4ee5\u5f80\u7684\u516c\u76ca\u6350\u52a9\u91d1\u984d\u3002<\/span><\/p>\n

\u8003\u616e\u5230\u9019\u53ef\u80fd\u7d66\u60a8\u5e36\u4f86\u95b1\u8b80\u9ad4\u9a57\u7684\u4e0b\u964d\uff0c\u6211\u5011\u5c0d\u6b64\u6df1\u8868\u907a\u61be\uff0c\u5e0c\u671b\u60a8\u53ef\u4ee5\u7406\u89e3\uff1b\u540c\u6642\u5982\u679c\u60a8\u8a8d\u70ba\u6587\u672b\u51fa\u73fe\u7684\u67d0\u4e9b\u5ee3\u544a\u5c0d\u60a8\u69cb\u6210\u4fb5\u6b0a\u6216\u662f\u9a37\u64fe\u7b49\uff0c\u8acb\u7acb\u5373\u9ede\u64ca\u93c8\u63a5\u4e0a\u5831\u7d66\u5fae\u4fe1\u5718\u968a\u3002<\/span><\/p>\n

\u7576\u7136\uff0c\u5728\u5e73\u8861\u7528\u6236\u95b1\u8b80\u9ad4\u9a57\u548c\u5718\u968a\u904b\u71df\u6210\u672c\u6642\uff0c\u6211\u5011\u6703\u6beb\u4e0d\u7336\u8c6b\u7684\u512a\u5148\u8003\u616e\u7528\u6236\u95b1\u8b80\u9ad4\u9a57\uff0c\u4e26\u5c07\u5c0d\u6b64\u4f5c\u51fa\u8abf\u6574\u3002\u5982\u679c\u60a8\u89ba\u5f97\u6587\u672b\u5ee3\u544a\u5df2\u7d93\u5f71\u97ff\u5230\u4e86\u60a8\u7684\u95b1\u8b80\u9ad4\u9a57\uff0c\u8acb\u96a8\u6642\u544a\u77e5\u6211\u5011\u3002<\/span><\/p>\n

\u6700\u5f8c\uff0c\u975e\u5e38\u611f\u8b1d\u60a8\u9577\u4e45\u4ee5\u4f86\u7684\u95dc\u6ce8\u548c\u652f\u6301\u3002<\/span><\/p>\n

\u6ce8\u610f\uff1a\u516c\u4f17\u53f7\u6240\u53d1\u5185\u5bb9\u5747\u4ec5\u4f9b\u533b\u836f\u4e13\u4e1a\u4eba\u58eb\u89c2\u770b\u3002<\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

#Deals \u4eca\u65e5 Jassen\u65d7\u4e0b\u5b50\u516c\u53f8Cilag\u5ba3\u5e03 \u4e0e\u6b27\u6d32\u836f\u4f01argenx\u8fbe\u6210\u5408\u4f5c\u534f\u8bae \u5171\u540c\u5f00\u53d1\u6297CD7 […]<\/p>\n","protected":false},"author":1,"featured_media":71144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71143"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=71143"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71143\/revisions"}],"predecessor-version":[{"id":71150,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71143\/revisions\/71150"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/71144"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=71143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=71143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=71143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}